The Importance of Implementing Good Pre-analytical Processes in Laboratories
Saturday, 30th November 2019 02 PM – 03 pm (GMT +8)
Many laboratories struggle with poor staining quality and invalid results everyday; and they may not be aware of what went wrong in the laboratory processes or how to mitigate the issue. Pre-analytical preparation is the first step in the specimen journey and it comprises of tissue collection, fixation, grossing of specimen, tissue processing, embedding and microtomy. It plays an important role in the success of tissue staining and pathology reporting. With optimally processed histology, pathologist is able to make a diagnosis accurately in a timely manner, and help the patient receive the right treatment promptly. Watch the recording to understand more!
Who should attend:
- Participants include Pathologists, Pathology lab directors, Histotechnologists, Pathology Residents/Trainees, Research Pathologists and Lab Scientists.
Key reason to attend:
- To understand Specimen handling, inclusive of handling of bone specimen, fixation, tissue processing, embedding and microtomy.
Faculty
Speaker |
||
|
 |
SpeakerDr Tan Soo YongMBBS, DipRCPath, FRCPath, DMJ, Dphil (Oxon) Associate Professor, Yong Loo Lin School of Medicine, NUS Senior Consultant, Department of Pathology, NUH International Advisor (West Pacific), Royal College of Pathologists |
Speaker |
|
 |
Dr. Richie Jara-LazaroPathologist, Medical & Scientific Affairs Roche Diagnostics Asia Pacific |
Speaker |
|
|
Dr. Richie Jara-LazaroPathologist, Medical & Scientific Affairs Roche Diagnostics Asia Pacific |
Joined Roche last February 2019, as Pathologist in the non-commercial division of the Medical and Scientific Affairs of Roche Diagnostics, Asia Pacific. Previously Associate Pathology Director in a leading global clinical trials organization, Q 2 Solutions (a Quintiles-Quest Joint Venture), Dr. Jara-Lazaro served as Principal Investigator for Companion Diagnostics and Oncology clinical trials in the central lab of its Asia-Pacific hub based in Singapore. Prior to this role, Dr. Jara-Lazaro worked for 7 years in Singapore General Hospital Department of Pathology, subspecialized in Breast and Urologic Pathology, and was Clinical Lead of the Digital Pathology Pilot Project in collaboration with the Singapore Ministry of Health. She has multiple peer-reviewed international publications; and is a manuscript reviewer for several pathology journals. She earned her Medical Degree in University of the East, is a Fellow of the Philippine Society of Pathologists, and Diplomate of the Singapore Academy of Medicine and UK Royal College of Pathologists. A 2 nd generation pathologist, she served in her home-province of Bacolod City after residency training in Philippine General Hospital. She co-headed family- owned clinical and histopath lab, started first FNA clinic in the province, and was faculty of the University of St. La Salle College of Medicine.
Challenges in Immunohistochemistry Assays Explained
Thursday, 12 November 2020 11 am – 12 pm (GMT +8)
In this part 1 session, the frequently asked IHC questions will be addressed. We will also be covering the importance of understanding nuances of various biomarker IHC assays. Join our live webinar on 12th November to hear from Dr. Lupe Manriquez, Principal Pathologist at Roche Tissue Diagnostics.
Who should attend:
- Participants include Pathologists, Pathology lab directors, Histotechnologists, Pathology Residents/Trainees, Research Pathologists and Lab Scientists.
Key reasons to attend:
- To understand the challenges and nuances in biomarker IHC assay staining and learn how to address them
- To gain insights on the value of quality control and quality assurance methods in histopathology.
- To learn about assay validation and verification for immunohistochemistry biomarker assays.
Faculty
Speaker |
||
|
 |
SpeakerDr. Lupe ManriquezPathologist, Medical & Scientific Affairs, Roche Diagnostics USA |
Dr. Lupe Manriquez is a Hematopathologist with academic, private practice experience now principal pathologist at Roche Tissue Diagnostics. She has been at Roche for 16+ years and have worked on platform and product development, manufacturing final acceptance testing, customer relations and education, and for the last 6 years in companion diagnosis (CDx). During her tenure in CDx her main project was SP263. Currently, she is in Medical and Scientific Affairs.
Speaker |
|
|
Dr. Richie Jara-LazaroPathologist, Medical & Scientific Affairs Roche Diagnostics Asia Pacific |
Speaker |
|
|
Dr. Richie Jara-LazaroPathologist, Medical & Scientific Affairs Roche Diagnostics Asia Pacific |
Joined Roche last February 2019, as Pathologist in the non-commercial division of the Medical and Scientific Affairs of Roche Diagnostics, Asia Pacific. Previously Associate Pathology Director in a leading global clinical trials organization, Q 2 Solutions (a Quintiles-Quest Joint Venture), Dr. Jara-Lazaro served as Principal Investigator for Companion Diagnostics and Oncology clinical trials in the central lab of its Asia-Pacific hub based in Singapore. Prior to this role, Dr. Jara-Lazaro worked for 7 years in Singapore General Hospital Department of Pathology, subspecialized in Breast and Urologic Pathology, and was Clinical Lead of the Digital Pathology Pilot Project in collaboration with the Singapore Ministry of Health. She has multiple peer-reviewed international publications; and is a manuscript reviewer for several pathology journals. She earned her Medical Degree in University of the East, is a Fellow of the Philippine Society of Pathologists, and Diplomate of the Singapore Academy of Medicine and UK Royal College of Pathologists. A 2 nd generation pathologist, she served in her home-province of Bacolod City after residency training in Philippine General Hospital. She co-headed family- owned clinical and histopath lab, started first FNA clinic in the province, and was faculty of the University of St. La Salle College of Medicine.
Maintaining Quality in Histopathology Laboratories
16 December 2020 11 am – 12.30 pm (GMT +8)
In this part 2 session, we will dive deep into the discussion of the histopathology laboratories entailing best practice standards to achieve quality IHC staining for pathology interpretation. For newly introduced biomarkers in a histopathology lab, assay validation or verification is required while for consistent optimal IHC staining and interpretation, quality checks are essential. How do we maintain quality in our labs? Join our live webinar on 16th December to hear from Dr. Bharathi Vennapusa and Dr. Anne Waydelich
Who should attend:
- Participants can be Pathologists, Pathology lab directors, Histotechnologists, Pathology Residents/Trainees, Research Pathologists and Lab Scientists.
Key reasons to attend:
- To understand the challenges and nuances in biomarker IHC assay staining and learn how to address them
- To gain insights on the value of quality control and quality assurance methods in histopathology.
- To learn about assay validation and verification for immunohistochemistry biomarker assays.
Faculty
Speaker |
||
|
 |
SpeakerDr. Bharathi VennapusaPathologist, Medical & Scientific Affairs, Roche Diagnostics USA |
Dr. Vennapusa is a pathologist working with the US Medical and Scientific Affairs field team supporting internal pharma tissue companion diagnostic assays including PD-L1 (SP142) assay. She served in this role since July 2018. Prior to that she worked at Ventana in Companion Diagnostics division in different roles including as a pathologist, medical director for Ventana’s CAP/CLIA laboratory and as director of clinical operations. During her tenure at Ventana she worked on several translational as well as companion diagnostic IHC, ISH and multiplexing assays as well as on digital pathology algorithms. She served as the lead development pathologist for PD-L1 (SP142) assay since the initiation of its development until the time of marketing of the assay for UC and NSCLC indications. Dr. Vennapusa received her medical education in India where she also trained as a general surgeon. She then pursued a career in pathology in US, where she did her residency in anatomic and clinical pathology (AP/CP) followed by fellowship training in molecular genetic pathology (MGP). She has several publications in molecular pathology and companion diagnostics and also has submitted and was granted patents for her work at Ventana. She has extensive experience in IHC, ISH, digital pathology, PCR, sequencing and NGS based assays.
Speaker |
|
 |
Dr. Anne WaydelichPhD, Scientist, Medical & Scientific Affairs, Roche Diagnostics Europe, Middle East & Latin America |
Speaker |
|
|
Dr. Anne WaydelichPhD, Scientist, Medical & Scientific Affairs, Roche Diagnostics Europe, Middle East & Latin America |
Dr. Anne Waydelich works at Roche Tissue Diagnostics within the Medical and Scientific Affairs group in the EMEA LATAM region (Europe, Middle East, Africa and Latin America and manages the Roche Tissue Diagnostics EMEA-LATAM Research & Quality control laboratory. She joined Roche (Ventana) in 2001 as customer support representative for the newly created division taking care of research customers (Discovery platforms). Since then, she held various function in the Roche Tissue Diagnostics EMEA-LATAM customer support organization, joining the Medical and Scientific Support function in 2014. She has achieved in 1999 a PhD in Molecular and Cellular Biology at University Louis Pasteur, Strasbourg, France.
Moderator |
|
|
Dr. Richie Jara-Lazaro, MDPathologist, Medical & Scientific Affairs Asia-Pacific |
Moderator |
|
|
Dr. Richie Jara-Lazaro, MDPathologist, Medical & Scientific Affairs Asia-Pacific |
Joined Roche last February 2019, as Pathologist in the non-commercial division of the Medical and Scientific Affairs of Roche Diagnostics, Asia Pacific. Previously Associate Pathology Director in a leading global clinical trials organization, Q 2 Solutions (a Quintiles-Quest Joint Venture), Dr. Jara-Lazaro served as Principal Investigator for Companion Diagnostics and Oncology clinical trials in the central lab of its Asia-Pacific hub based in Singapore. Prior to this role, Dr. Jara-Lazaro worked for 7 years in Singapore General Hospital Department of Pathology, subspecialized in Breast and Urologic Pathology, and was Clinical Lead of the Digital Pathology Pilot Project in collaboration with the Singapore Ministry of Health. She has multiple peer-reviewed international publications; and is a manuscript reviewer for several pathology journals. She earned her Medical Degree in University of the East, is a Fellow of the Philippine Society of Pathologists, and Diplomate of the Singapore Academy of Medicine and UK Royal College of Pathologists. A 2 nd generation pathologist, she served in her home-province of Bacolod City after residency training in Philippine General Hospital. She co-headed family- owned clinical and histopath lab, started first FNA clinic in the province, and was faculty of the University of St. La Salle College of Medicine.
